Furthermore, we stratified patients into different risk subgroups by several clinicopathologic parameters (age, gender, ALT, AFP, level, main tumor size, cirrhosis, BCLC stage, TNM stage, and CLIP stage) using the two-hub gene-based signature. This evidence concerns the gene AFP and neoplasm.